Do analysts prefer CTSO or FONR?

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 1,197.68%. Given Cytosorbents' higher probable upside, equities research analysts plainly believe Cytosorbents is more favorable than Fonar. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Fonar 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, CTSO or FONR?

Fonar has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytosorbents $37.06M 0.70 -$8.20M -$0.19 N/A Fonar $105.34M 1.12 $8.33M $1.00 19.09

Is CTSO or FONR more profitable?

Fonar has a net margin of 6.35% compared to Cytosorbents' net margin of -31.85%. Fonar's return on equity of 4.12% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -31.85% -235.57% -37.88% Fonar 6.35% 4.12% 3.07%

Does the media favor CTSO or FONR?

In the previous week, Fonar had 3 more articles in the media than Cytosorbents. MarketBeat recorded 4 mentions for Fonar and 1 mentions for Cytosorbents. Fonar's average media sentiment score of 0.77 beat Cytosorbents' score of 0.00 indicating that Fonar is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fonar 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NYXH or CTSO?

Cytosorbents has higher revenue and earnings than Nyxoah. Cytosorbents is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nyxoah $11.33M 4.76 -$101.92M -$2.48 N/A Cytosorbents $37.06M 0.70 -$8.20M -$0.19 N/A

Is NYXH or CTSO more profitable?

Cytosorbents has a net margin of -31.85% compared to Nyxoah's net margin of -543.21%. Nyxoah's return on equity of -163.73% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Nyxoah -543.21% -163.73% -80.24% Cytosorbents -31.85% -235.57% -37.88%

Does the media refer more to NYXH or CTSO?

In the previous week, Nyxoah had 5 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for Nyxoah and 1 mentions for Cytosorbents. Nyxoah's average media sentiment score of 0.19 beat Cytosorbents' score of 0.00 indicating that Nyxoah is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nyxoah 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IINN or CTSO?

Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,197.68%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, IINN or CTSO?

Cytosorbents has higher revenue and earnings than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inspira Technologies OXY B.H.N. $289K 176.64 -$13.22M N/A N/A Cytosorbents $37.06M 0.70 -$8.20M -$0.19 N/A

Does the media prefer IINN or CTSO?

In the previous week, Inspira Technologies OXY B.H.N. and Inspira Technologies OXY B.H.N. both had 1 articles in the media. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CTSO or QTEX?

Cytosorbents presently has a consensus price target of $5.38, indicating a potential upside of 1,197.68%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities analysts clearly believe Cytosorbents is more favorable than Inspira Technologies OXY B.H.N.. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Inspira Technologies OXY B.H.N. 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, CTSO or QTEX?

Cytosorbents has higher revenue and earnings than Inspira Technologies OXY B.H.N.. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytosorbents $37.06M 0.70 -$8.20M -$0.19 N/A Inspira Technologies OXY B.H.N. $290K 174.79 -$13.22M N/A N/A

Does the media favor CTSO or QTEX?

In the previous week, Inspira Technologies OXY B.H.N. had 1 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for Inspira Technologies OXY B.H.N. and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.00 equaled Inspira Technologies OXY B.H.N.'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inspira Technologies OXY B.H.N. 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cytosorbents (CTSO) Competitors

$0.41 -0.04 (-9.76%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 +0.00 (+0.43%)

As of 06:41 PM Eastern

Compare

CTSO vs. FONR, NYXH, VANI, IINN, and QTEX

Should you buy Cytosorbents stock or one of its competitors? MarketBeat compares Cytosorbents with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytosorbents include Fonar (FONR), Nyxoah (NYXH), Vivani Medical (VANI), Inspira Technologies OXY B.H.N. (IINN), and Inspira Technologies OXY B.H.N. (QTEX). These companies are all part of the "medical equipment" industry.

How does Cytosorbents compare to Fonar?

Cytosorbents (NASDAQ:CTSO) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Fonar has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.70	-$8.20M	-$0.19	N/A
Fonar	$105.34M	1.12	$8.33M	$1.00	19.09

In the previous week, Fonar had 3 more articles in the media than Cytosorbents. MarketBeat recorded 4 mentions for Fonar and 1 mentions for Cytosorbents. Fonar's average media sentiment score of 0.77 beat Cytosorbents' score of 0.00 indicating that Fonar is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fonar	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fonar has a net margin of 6.35% compared to Cytosorbents' net margin of -31.85%. Fonar's return on equity of 4.12% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Fonar	6.35%	4.12%	3.07%

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 50.6% of Fonar shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by insiders. Comparatively, 7.9% of Fonar shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Fonar has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Cytosorbents presently has a consensus target price of $5.38, suggesting a potential upside of 1,197.68%. Given Cytosorbents' higher probable upside, equities research analysts plainly believe Cytosorbents is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Fonar beats Cytosorbents on 12 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to Nyxoah?

Nyxoah (NASDAQ:NYXH) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Nyxoah had 5 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for Nyxoah and 1 mentions for Cytosorbents. Nyxoah's average media sentiment score of 0.19 beat Cytosorbents' score of 0.00 indicating that Nyxoah is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nyxoah	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nyxoah has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Cytosorbents has a net margin of -31.85% compared to Nyxoah's net margin of -543.21%. Nyxoah's return on equity of -163.73% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nyxoah	-543.21%	-163.73%	-80.24%
Cytosorbents	-31.85%	-235.57%	-37.88%

Nyxoah presently has a consensus target price of $7.67, indicating a potential upside of 451.56%. Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,197.68%. Given Cytosorbents' higher probable upside, analysts clearly believe Cytosorbents is more favorable than Nyxoah.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

32.9% of Cytosorbents shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cytosorbents has higher revenue and earnings than Nyxoah. Cytosorbents is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$11.33M	4.76	-$101.92M	-$2.48	N/A
Cytosorbents	$37.06M	0.70	-$8.20M	-$0.19	N/A

Summary

Nyxoah and Cytosorbents tied by winning 8 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Cytosorbents has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
Cytosorbents	$37.06M	0.70	-$8.20M	-$0.19	N/A

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 53.3% of Vivani Medical shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vivani Medical has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-264.04%	-79.85%
Cytosorbents	-31.85%	-235.57%	-37.88%

Vivani Medical currently has a consensus price target of $3.50, indicating a potential upside of 204.35%. Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 1,197.68%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vivani Medical has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

In the previous week, Cytosorbents had 1 more articles in the media than Vivani Medical. MarketBeat recorded 1 mentions for Cytosorbents and 0 mentions for Vivani Medical. Vivani Medical's average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score.

Company	Overall Sentiment
Vivani Medical	Neutral
Cytosorbents	Neutral

Summary

Cytosorbents beats Vivani Medical on 9 of the 12 factors compared between the two stocks.

How does Cytosorbents compare to Inspira Technologies OXY B.H.N.?

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Inspira Technologies OXY B.H.N. has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

In the previous week, Inspira Technologies OXY B.H.N. and Inspira Technologies OXY B.H.N. both had 1 articles in the media. Inspira Technologies OXY B.H.N.'s average media sentiment score of 0.00 equaled Cytosorbents'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 6.6% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inspira Technologies OXY B.H.N. has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Inspira Technologies OXY B.H.N.'s return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Cytosorbents	-31.85%	-235.57%	-37.88%

Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,197.68%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytosorbents has higher revenue and earnings than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$289K	176.64	-$13.22M	N/A	N/A
Cytosorbents	$37.06M	0.70	-$8.20M	-$0.19	N/A

Summary

Inspira Technologies OXY B.H.N. and Cytosorbents tied by winning 6 of the 12 factors compared between the two stocks.

How does Cytosorbents compare to Inspira Technologies OXY B.H.N.?

Cytosorbents (NASDAQ:CTSO) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 6.6% of Cytosorbents shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Inspira Technologies OXY B.H.N. had 1 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for Inspira Technologies OXY B.H.N. and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.00 equaled Inspira Technologies OXY B.H.N.'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inspira Technologies OXY B.H.N.	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytosorbents has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 4.06, indicating that its stock price is 306% more volatile than the broader market.

Cytosorbents has higher revenue and earnings than Inspira Technologies OXY B.H.N..

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.70	-$8.20M	-$0.19	N/A
Inspira Technologies OXY B.H.N.	$290K	174.79	-$13.22M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Cytosorbents presently has a consensus price target of $5.38, indicating a potential upside of 1,197.68%. Given Cytosorbents' stronger consensus rating and higher possible upside, equities analysts clearly believe Cytosorbents is more favorable than Inspira Technologies OXY B.H.N..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inspira Technologies OXY B.H.N.	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Inspira Technologies OXY B.H.N. beats Cytosorbents on 7 of the 13 factors compared between the two stocks.

Get Cytosorbents News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTSO vs. The Competition

Export

Metric	Cytosorbents	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.82M	$8.48B	$6.49B	$11.99B
Dividend Yield	N/A	2.52%	2.67%	5.57%
P/E Ratio	-2.18	16.16	23.92	23.74
Price / Sales	0.70	7.13	507.57	108.00
Price / Cash	N/A	17.45	26.99	37.25
Price / Book	4.60	3.55	10.28	6.78
Net Income	-$8.20M	$225.32M	$3.57B	$337.51M
7 Day Performance	-11.48%	-1.06%	-1.43%	-2.72%
1 Month Performance	-31.99%	2.21%	3.27%	1.87%
1 Year Performance	-60.92%	-3.10%	23.37%	26.60%

Cytosorbents Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTSO Cytosorbents	1.4422 of 5 stars	$0.41 -9.8%	$5.38 +1,197.7%	-56.7%	$28.82M	$37.06M	N/A	220	Gap Up
FONR Fonar	2.9905 of 5 stars	$19.12 +0.0%	N/A	N/A	$117.90M	$104.35M	19.12	480
NYXH Nyxoah	2.9665 of 5 stars	$2.97 -1.8%	$7.67 +158.6%	-81.1%	$115.51M	$11.33M	N/A	110	Gap Up
VANI Vivani Medical	2.3285 of 5 stars	$1.32 +2.3%	$3.50 +165.2%	+2.6%	$113.83M	N/A	N/A	20	Gap Up
IINN Inspira Technologies OXY B.H.N.	0.705 of 5 stars	$3.08 +0.3%	$2.00 -35.1%	+95.6%	$110.72M	$289K	N/A	20	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTSO) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytosorbents (CTSO) Competitors

CTSO vs. FONR, NYXH, VANI, IINN, and QTEX

How does Cytosorbents compare to Fonar?

Summary

How does Cytosorbents compare to Nyxoah?

Summary

How does Cytosorbents compare to Vivani Medical?

Summary

How does Cytosorbents compare to Inspira Technologies OXY B.H.N.?

Summary

How does Cytosorbents compare to Inspira Technologies OXY B.H.N.?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytosorbents (CTSO) Competitors

CTSO vs. FONR, NYXH, VANI, IINN, and QTEX

How does Cytosorbents compare to Fonar?

Which has higher valuation & earnings, CTSO or FONR?

Does the media favor CTSO or FONR?

Is CTSO or FONR more profitable?

Do institutionals and insiders have more ownership in CTSO or FONR?

Which has more risk & volatility, CTSO or FONR?

Do analysts prefer CTSO or FONR?

Summary

How does Cytosorbents compare to Nyxoah?

Does the media refer more to NYXH or CTSO?

Which has more risk & volatility, NYXH or CTSO?

Is NYXH or CTSO more profitable?

Do analysts rate NYXH or CTSO?

Do institutionals & insiders believe in NYXH or CTSO?

Which has stronger valuation and earnings, NYXH or CTSO?

Summary

How does Cytosorbents compare to Vivani Medical?

Which has higher earnings and valuation, VANI or CTSO?

Do insiders & institutionals believe in VANI or CTSO?

Is VANI or CTSO more profitable?

Do analysts prefer VANI or CTSO?

Which has more volatility and risk, VANI or CTSO?

Does the media prefer VANI or CTSO?

Summary

How does Cytosorbents compare to Inspira Technologies OXY B.H.N.?

Which has more risk & volatility, IINN or CTSO?

Does the media prefer IINN or CTSO?

Do insiders & institutionals have more ownership in IINN or CTSO?

Is IINN or CTSO more profitable?

Do analysts recommend IINN or CTSO?

Which has stronger valuation & earnings, IINN or CTSO?

Summary

How does Cytosorbents compare to Inspira Technologies OXY B.H.N.?

Do insiders and institutionals believe in CTSO or QTEX?

Does the media favor CTSO or QTEX?

Which has more risk & volatility, CTSO or QTEX?

Which has preferable valuation and earnings, CTSO or QTEX?

Is CTSO or QTEX more profitable?

Do analysts rate CTSO or QTEX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools